GH1 and diabetes mellitus: The limitation in our study is the difficulty to start growth hormone replacement therapy due to the high cost in our health system, which could influence the metabolic outcomes; however, the diabetes multivariate predictor model did not show a statistical significance when hyposomatotropism was controlled.